http://www.zibb.com/all/theme/cq/Insmed+Incorporated Zibb. The Global business search engine. en-US search@zibb.com (RB Search)Copyright (c) 2007 Reed Business Information. All rights reserved.Mon, 27 Jul 2009 13:10:40 GMTMon, 27 Jul 2009 13:10:40 GMT608831http://www.zibb.com/all/theme/cq/Insmed+Incorporated http://www.zibb.com/images/en/g_zibb_logo_beta.gif http://www.bio-medicine.org/medicine-news-1/Insmed-Provides-Update-on-Supply-of-IPLEX-28TM-29-52763-1/Health,... ... ...RICHMOND Va. July 27 /- Insmed Inc. (Nasdaq: ... ...,Insmed,Provides,Update,on,Supply,of,IPLEX(TM),medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine newshttp://www.bio-medicine.org/medicine-news-1/Insmed-Provides-Update-on-Supply-of-IPLEX-28TM-29-52763-1/Insmed IncorporatedMon, 27 Jul 2009 13:10:40 GMThttp://www.tercica.com/content.php?content_id=58Our primary goal in these partnerships is to provide our development commercialization expertise to companies whose products offer therapeutic benefits to patients with endocrine, metabolic, or related orphan diseases.http://www.tercica.com/content.php?content_id=58Insmed Incorporatedhttp://www.holdrs.com/holdrs/main/index.asp?Action=Headlines&Description=&Image=&symb=INSM&sid=205428Copyright © 2009 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by Interactive Data Real-Time Services and subject to the Terms of Use.http://www.holdrs.com/holdrs/main/index.asp?Action=Headlines&Description=&Image=&symb=INSM&sid=205428Insmed Incorporatedhttp://www.dfb.com/index.php?id=23&tx_ttnews[pS]=1203199508&tx_ttnews[pointer]=1&tx_ttnews[tt_news]=33&tx_ttnews[backPid]=61&cHash=baacb9735dIPLEX was approved by the FDA in December 2005 for the treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to GH.http://www.dfb.com/index.php?id=23&tx_ttnews[pS]=1203199508&tx_ttnews[pointer]=1&tx_ttnews[tt_news]=33&tx_ttnews[backPid]=61&cHash=baacb9735dInsmed Incorporatedhttp://www.intersouth.com/success/insmed.aspxInsmed Incorporated was founded upon pharmaceutical research performed at the University of Virginia. The technology, developed by Dr. Joseph Larner while he was Chairman of the Department of Pharmacology, was licensed to the company and focused on therapeutics for Type II adult onset diabetes.http://www.intersouth.com/success/insmed.aspxInsmed Incorporatedhttp://www.drugs.com/nda/somatokine_050610.htmlDrugs.com - prescription drug and over the counter medicine information available on over 24,000 approved medications and pharmaceuticals, including side effects and drug interactions.http://www.drugs.com/nda/somatokine_050610.htmlInsmed Incorporatedhttp://www.newratings.com/headlines/INSMED-INC-_US4576692085.htmlCopyright © 2002 - 2008 newratings.com GmbH | Legal | Licensing Quote data provided by IS.eFinance Solutions (powered by IS.Teledata AG) using StandardPoor's ComStock Inc. and others. Delay times are 15 mins for European exchanges and NASDAQ, 20 mins for NYSE and AMEX.http://www.newratings.com/headlines/INSMED-INC-_US4576692085.htmlInsmed Incorporatedhttp://www.quotelinks.com/companies/insm.htmlStock quotes, news and charts for Insmed Incorporated Quotes Simple Charts Stock News MSN Investor Thomson Investors Short Interest Yahoo Finance CBS Marketwatch BigCharts StockCharts.com Yahoo Lycos Investing Quicken Yahoo News Quote.com (Lycos) CNET news ZDNet Business Week Stock earnings,http://www.quotelinks.com/companies/insm.htmlInsmed Incorporatedhttp://www.apria.com/resources/1,2725,494-877135,00.htmlWith this orphan designation in Europe Premacure is eligible for protocol assistance (scientific advice), as well as fee reductions for pre-authorisation activities and inspections.http://www.apria.com/resources/1,2725,494-877135,00.htmlInsmed Incorporatedhttp://www.biospace.com/news_story.aspx?NewsEntityId=48184BRISBANE, Calif. & RICHMOND, Va.--(BUSINESS WIRE)--Tercica, Inc., (Nasdaq:TRCA) and Insmed Incorporated (Nasdaq:INSM) today announced that Tercica, Insmed and Genentech, Inc.http://www.biospace.com/news_story.aspx?NewsEntityId=48184Insmed Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=45847The request comes as a result of several Italian Court rulings ordering the Italian National Health System to provide the drug to specific ALS patients who have petitioned the Court.http://www.pharmacychoice.com/News/article.cfm?Article_ID=45847Insmed Incorporatedhttp://www.twst.com/notes/articles/tas206.htmlTWST: What is Insmed? Mr. Young: Insmed is a biotechnology company that's focused on modulating and regulating the IGF-1 (Insulin-like Growth Factor-1) pathway.http://www.twst.com/notes/articles/tas206.htmlInsmed Incorporatedhttp://www.packwire.com/news/ng.asp?n=55546-insmed-trials-encourage20/10/2004 - Biopharmaceutical company, Insmed, are to commence clinical development of a small molecule tyrosine kinase inhibitor, which has demonstrated anti-tumour activity in preclinical studies of breast, lung, pancreatic and prostate tumours.http://www.packwire.com/news/ng.asp?n=55546-insmed-trials-encourageInsmed Incorporatedhttp://www.bioexchange.com/news/news_page.cfm?id=21228\r\n\r\nIra D. Goldfine, M.D. Professor of Medicine at UCSF will lead the\r\ninvestigative efforts with IGF1 receptor antagonists to identify the\r\ncompound with an ideal risk/benefit ratio to enter clinical trials.http://www.bioexchange.com/news/news_page.cfm?id=21228Insmed Incorporatedhttp://www.allbusiness.com/legal/law-firms/3949076-1.htmlRICHMOND, Va. -- Insmed Incorporated (Nasdaq: INSM) announced today the addition of Henry Bunsow as outside counsel to its legal team. Mr. Bunsow was recently named one of the top 25 patent attorneys in California. Henry Bunsow is the Managing Partner of the Northern California offices of Howreyhttp://www.allbusiness.com/legal/law-firms/3949076-1.htmlInsmed Incorporatedhttp://www.rhomanagement.com/venture_capital/vc_news/06/tercica_120606.htmlTercica, Inc. (Nasdaq:TRCA) today announced that a jury in the US District Court for the Northern District of California found that Insmed Incorporated and Insmed Therapeutic Proteins, Inc. have infringed Genentech's US Patent No. 5,258,287; willfully infringed US Patent No.http://www.rhomanagement.com/venture_capital/vc_news/06/tercica_120606.htmlInsmed Incorporatedhttp://www.micromedex.com/pressroom/news_feeds/?story_ID=108140&category=18Get the news that matters to you. Create your own customized news service that delivers the latest information directly to you. Plus you can view the most current press releases from Micromedex.http://www.micromedex.com/pressroom/news_feeds/?story_ID=108140&category=18Insmed Incorporatedhttp://www.buyandhold.com/StockMgr?request=display.content&symbol=INSM&ContentURL=%2Fcustom%2Fbuyandhold%2Dcom%2Fhtml%2Dnews%2Easp&symb=INSMCopyright © 2006 MarketWatch, Inc. All rights reserved. Please see our Terms of Use. MarketWatch, the MarketWatch logo, and BigCharts are registered trademarks of MarketWatch, Inc. Intraday data provided by ComStock, an Interactive Data Company and subject to the Terms of Use.http://www.buyandhold.com/StockMgr?request=display.content&symbol=INSM&ContentURL=%2Fcustom%2Fbuyandhold%2Dcom%2Fhtml%2Dnews%2Easp&symb=INSMInsmed Incorporatedhttp://www.mwe.com/index.cfm/fuseaction/media.prdetail/object_id/55a85de1-273a-4ddc-aead-20ea14d8055b.cfmPALO ALTO, CA (December 7, 2006) — In a closely watched biotechnology case relating to recombitantly produced hormones that enable children of short stature to grow, a California jury ruled in favor of McDermott Will & Emery client, Tercica, Inc., and Genentech.http://www.mwe.com/index.cfm/fuseaction/media.prdetail/object_id/55a85de1-273a-4ddc-aead-20ea14d8055b.cfmInsmed Incorporatedhttp://www.dailyprogress.com/servlet/Satellite?pagename=CDP%2FMGArticle%2FRTD_BasicArticle&c=MGArticle&cid=1149193563700&path=!businessInsmed Inc. has settled its long-standing court case with its California rival. It has forced the Richmond company to pull from the market its drug -- and main revenue stream -- for treatment of children who are abnormally short.http://www.dailyprogress.com/servlet/Satellite?pagename=CDP%2FMGArticle%2FRTD_BasicArticle&c=MGArticle&cid=1149193563700&path=!businessInsmed Incorporatedhttp://www.tercica.com/content.php?content_id=8At Tercica, the depth of our commitment to endocrine and metabolic health compels us to continually seek out more effective treatment options. To that end, we maintain a steady stream of products in our pipeline, all at various stages of development.http://www.tercica.com/content.php?content_id=8Insmed Incorporatedhttp://www.tercica.com/content.php?content_id=11Combination Products with Genentech In July 2007, Tercica announced a worldwide collaboration with Genentech in which Tercica will develop and commercialize two next-generation growth hormone products.http://www.tercica.com/content.php?content_id=11Insmed Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=51323/CNW/ - Insmed Inc., (NASDAQ: INSM) announced today that it has restructured its operations as a result of the litigation settlement with Tercica Inc. (NASDAQ: TRCA) and Genentech Inc. (NYSE: DNA), which was announced yesterday, ending all litigation between the parties.http://www.pharmacychoice.com/News/article.cfm?Article_ID=51323Insmed Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=520982007 MAR 19 - (NewsRx.com) -- Insmed Inc., (NASDAQ: INSM) announced that it has restructured its operations as a result of the litigation settlement with Tercica Inc. (NASDAQ: TRCA) and Genentech Inc. (NYSE: DNA), which was announced yesterday, ending all litigation between the parties.http://www.pharmacychoice.com/News/article.cfm?Article_ID=52098Insmed Incorporatedhttp://www.pharmacychoice.com/News/article.cfm?Article_ID=24176RICHMOND, Va.--(BUSINESS WIRE)--March 15, 2006--Insmed Incorporated (NASDAQ:INSM) today announced that the underwriters of its previously announced public offering, have exercised in full the option to purchase an additional 3,000,000 shares of Insmed's common stock.http://www.pharmacychoice.com/News/article.cfm?Article_ID=24176Insmed Incorporated